Navigation Links
Chimerix Presents Data Highlighting Burden Of Care Associated With Current Antiviral Therapies In Stem Cell Transplantation
Date:9/21/2012

negatively impact both stem cell and organ transplant recipients.  CMX001 has demonstrated clinical activity in the prevention of CMV infection and preemption of AdV infection post-HSCT.

The data presented were derived from CMX001 Study 201*, Chimerix's Phase 2 study evaluating CMX001 for the prevention of CMV disease in HSCT recipients.  The subset of patients described above received placebo or an inactive, low dose of CMX001.

Chimerix is planning to explore further the potential benefit of CMX001 in efficacy and safety, and reducing the burden of care. Chimerix is initiating a Phase 3 clinical trial of CMX001 for the prevention of CMV infection in adult CMV seropositive HSCT recipients, in which all subjects will be followed through 24 weeks post-transplant.

About Chimerix and CMX001
Chimerix is developing novel oral antiviral therapeutics with the potential to improve outcomes for patients in multiple therapeutic areas, including transplant, oncology, acute care and global health.  The company's proprietary lipid technology has given rise to two clinical-stage lipid acyclic nucleoside phosphonates, CMX001 and CMX157, which have demonstrated the potential for enhanced activity and safety compared with currently approved drugs. 

CMX001 is a novel, broad-spectrum, oral antiviral that inhibits dsDNA viruses, including CMV, AdV, BK virus and herpes simplex virus.  CMX001 has completed Phase 2 clinical development for the prophylaxis of CMV in HSCT recipients and is in Phase 2 development for the preemption and treatment of AdV infection.  To date, more than 800 patients have been dosed with CMX001 in controlled clinical trials and open-label treatment protocols.  Chimerix has completed an End of Phase 2 meeting with the FDA and is preparing to initiate Phase 3 clinical development of CMX001 for the prophylaxis of CMV in HSCT recipients in early 2013.   

In addition to its co
'/>"/>

SOURCE Chimerix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Chimerix Signs Worldwide License Agreement With Merck For CMX157, A Novel Candidate For The Treatment Of HIV
2. Chimerixs Broad Spectrum Antiviral Therapeutic, CMX001, Demonstrates Potential To Mitigate BK Virus Associated End-Organ Disease In Clinical Study
3. Chimerix Announces BK Virus Data In Late-Breaking Poster Session At The 24th International Congress Of The Transplantation Society
4. Jennerex Presents Positive Clinical Data from Phase 2 Trial of JX-594 in Sorafenib-Refractory Liver Cancer Patients
5. Sorbent Therapeutics Presents CLP1001 Phase 2a Study Results at the 16th Annual Meeting of the Heart Failure Society of America
6. Mettler Toledo Presents In-depth Guidance to Comply with New USP Chapters 41 and 1251 on Balances Used for Quantitative Analysis in the Pharma QC Lab
7. Elevation Pharmaceuticals Presents Positive Phase 2b Results for EP-101 in COPD Patients at the European Respiratory Society Annual Congress
8. Informex Global Pharma Sourcing 2012 Presents Key Strategies & Insight For Business Success
9. Epigenomics Presents Significant Opportunities for Investment and Product Development, According to New Biotech Market Research
10. Cardium Presents Second Quarter 2012 Financial Results And Reports On Recent Developments
11. Inovio Initiates H1N1 Universal Influenza Vaccine Clinical Trial Targeting Over-65 Population, Which Represents 90% of Flu Deaths
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... novel wearable injector slightly larger than an Oreo cookie may ... prescription drugs in the large doses required to treat a ... and genetic disorders.  An emerging biologic drugs ... to analysts.   Many of these drugs will require a new ...
(Date:1/14/2014)... , Jan. 14, 2014 Dynamic Healthcare Services, Inc. ("DHS"), ... that it acquired Progressive Home Medical Equipment, Inc. ("Progressive") of ... The terms of the acquisition were not disclosed. ... company providing a wide range of sleep, mobility, and respiratory ...
(Date:1/14/2014)... Jan. 14, 2014   Oligomerix, Inc. , a privately held ... Alzheimer,s disease (AD) and related neurodegenerative disorders, announced today ... Valhalla, NY as of January 15, 2014 ... New York Medical College. Oligomerix, which is ...
Breaking Medicine Technology:Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... Feb. 28, 2012 Landauer, Inc. (NYSE: LDR) ... quarterly cash dividend of $0.55 per share for the second ... 3, 2012, to shareholders of record on March 9, 2012. ... global provider of technical and analytical services to determine occupational ...
... N.C., Feb. 28, 2012  In an effort to maximize ... and biotech market research leaders must constantly evaluate the ... executives need to understand the optimal balance of external ... productivity in the quickly changing healthcare industry. ...
Cached Medicine Technology:Current Study Offers Window into Automation & Outsourcing Practices Within Top Pharmaceutical Market Research Groups 2
(Date:4/17/2014)... University School of Medicine (BUSM) have discovered that ... an experimental model. The findings, reported in the ... , may lead to more effective treatments for ... of the leading causes of illness and death ... impact by limiting the productivity of workers and ...
(Date:4/17/2014)... off depression among retirees, particularly among those who live ... The Journals of Gerontology, Series B: Psychological Sciences and ... Use and Depression Among Retired Older Adults in the ... that Internet use reduced the probability of a depressed ... , Late-life depression affects between 5 and 10 million ...
(Date:4/17/2014)... to find a colored ribbon representing a disease. A pink ... color ribbon does one think of with lung cancer?, Although ... suffering from the disease, black may be the only one ... lung cancer patients, primarily smokers between the ages of 51 ... stigma often felt by these patients, the emotional toll it ...
(Date:4/17/2014)... world is less than 40 years away from a ... and governments, according to a top scientist at the ... in human history, food production will be limited on ... and energy," said Dr. Fred Davies, senior science advisor ... could become as politically destabilizing by 2050 as energy ...
(Date:4/17/2014)... adrenaline after they suffer a cardiac arrest outside of ... long-term, according to new research conducted at St. Michael,s ... a cardiac arrest get adrenaline, which has been the ... Dr. Steve Lin, an emergency physician and trauma team ... treatment, long-term survival rates of patients who suffer a ...
Breaking Medicine News(10 mins):Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:Internet use may cut retirees' depression 2Health News:Unraveling the 'black ribbon' around lung cancer 2Health News:Food shortages could be most critical world issue by mid-century 2Health News:Adrenaline does little to increase patient's survival after cardiac arrest 2
... , , , ... Association (AVMA) is unveiling a new online pre s ... the tools and resources available to journalists. , , The ... and often controversial issues in veterinary medicine as easy as possible for journalists ...
... VOORHEES, N.J., Aug. 13 The rates and severity ... by several factors, including antimicrobial use, other drug-prescribing factors, infection ... C. difficile that is more resistant to fluoroquinolones ... is crucial for healthcare professionals to be aware of these ...
... , MUMBAI, India, Aug. 13 Sun ... PHARMA, BSE: 524715) today announced that as of 11:59 p.m. ... (HSR) Act waiting period, previously granted by the U.S. Federal ... Department of Justice for the Tender Offer by Alkaloida Chemical ...
... KIBBUTZ SHAMIR, Israel, Aug. 13 Shamir Optical Industry Ltd. ... of innovative products and technology to the ophthalmic lens market, today ... 2009. , , For the quarter ended June ... million for the same period in 2008. The decrease in revenues ...
... health have found that its impact varies dramatically with age. ... bone strength in young people, it may protect against osteoporosis, ... team at the University of Edinburgh has shown that a ... by cannabis called the type 1 cannabinoid receptor (CB1) ...
... 2009: Research at the University of Liverpool has found ... dictate the physical state of superstructures. The ... distinguishable by their inability to be superimposed onto their ... just one mirror form of amino acids and DNA, ...
Cached Medicine News:Health News:AVMA Unveils Improved Online Press Room to Help Journalists 2Health News:AVMA Unveils Improved Online Press Room to Help Journalists 3Health News:Clostridium difficile Infection: Tracking a Virulent Pathogen 2Health News:Sun Pharmaceutical to File HSR Application for Taro Tender Offer 2Health News:Sun Pharmaceutical to File HSR Application for Taro Tender Offer 3Health News:Shamir Optical Industry Ltd. Reports Second Quarter 2009 Results 2Health News:Shamir Optical Industry Ltd. Reports Second Quarter 2009 Results 3Health News:Shamir Optical Industry Ltd. Reports Second Quarter 2009 Results 4Health News:Shamir Optical Industry Ltd. Reports Second Quarter 2009 Results 5Health News:Shamir Optical Industry Ltd. Reports Second Quarter 2009 Results 6Health News:Shamir Optical Industry Ltd. Reports Second Quarter 2009 Results 7Health News:Shamir Optical Industry Ltd. Reports Second Quarter 2009 Results 8Health News:Shamir Optical Industry Ltd. Reports Second Quarter 2009 Results 9Health News:Shamir Optical Industry Ltd. Reports Second Quarter 2009 Results 10Health News:Molecules wrestle for supremacy in creation of superstructures 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: